The markers that break first
Metabolic dysfunction is a decade-long story, and most people only read the last chapter. Fasting glucose and HbA1c — the markers a standard physical checks — are lagging: they stay normal while the pancreas quietly over-secretes insulin to hold the line. By the time glucose finally drifts up, compensation has already failed and years of warning have been wasted. This chapter is about reading the leading markers instead.
Fasting insulin — the single highest-value metabolic number
If you add one test to a standard panel, make it fasting insulin. The population range runs absurdly wide (~2–24 mIU/L), but the optimal target is below 5 mIU/L. A fasting insulin of 12 with a perfectly normal glucose is not "fine" — it is the pancreas working overtime, the earliest sign of insulin resistance, often present a decade before glucose moves. It must be drawn truly fasted (8–12 hours), and insulin assays vary between labs, so trend within one lab.
There is a direct protocol consequence: growth hormone is counter-regulatory to insulin, so GH secretagogues push insulin and glucose upward. When fasting insulin is already elevated (above ~8 mIU/L), stacking a GH secretagogue on top drives metabolism the wrong way — which is exactly why this one number gates that decision.
HOMA-IR — insulin and glucose, read together
HOMA-IR combines fasting insulin and fasting glucose into a single insulin-resistance index (insulin × glucose ÷ 405). Optimal is below 1.0; 2.0 and above is established resistance, 3.0 is severe. Because it uses both inputs, it catches the compensating pancreas that either marker alone would miss — but both inputs must come from the same true-fasted draw.
HbA1c and fasting glucose — the lagging confirmation
HbA1c reflects average glucose over ~90 days; optimal is below 5.3%. It is convenient but confounded: iron-deficiency anemia falsely raises it (red cells live longer), and hemolysis or high red-cell turnover falsely lowers it. Fasting glucose optimal is 72–85 mg/dL; it is the last marker to break in the insulin-resistance cascade, and it is noisy — process the sample promptly or in-tube glycolysis drags the number down. Treat both as confirmation of what insulin and HOMA-IR already told you, not as the front line.
C-peptide and fructosamine — the supporting cast
C-peptide is released one-for-one with endogenous insulin and is not cleared by the liver, so it reads beta-cell output more cleanly than insulin itself — useful for telling "restored sensitivity" apart from "beta-cell exhaustion" when fasting insulin falls. Fructosamine reflects average glucose over just 2–3 weeks, a faster-feedback alternative to HbA1c when you want to see a recent intervention working before the 90-day marker catches up.
Reading the panel together
Read insulin and HOMA-IR first — they are the leading markers and they buy you the years that matter. Let HbA1c and glucose confirm rather than lead, and remember their artifacts before you trust a surprising value. On GLP-1 agonists you will watch insulin, HOMA-IR, and HbA1c fall together; on GH-class protocols you will watch them drift up and respond by managing carbohydrate placement and timing rather than ignoring the signal.
Educational only; not medical or dosing advice. Always draw the fasting markers after a true 8–12 hour fast.